Title Page
국문요약
Contents
ABBREVIATION LIST 8
INTRODUCTION 9
METHODS 10
RESULTS 14
DISCUSSION 17
CONCLUSION 20
References 22
ABSTRACT 59
Table 1. Baseline characteristics of patients on warfarin or direct oral anticoagulants 26
Table 2. Incidence rates and hazard ratios for clinical outcomes with warfarin versus direct oral anticoagulants in the total study population 29
Table 3. Incidence rates and hazard ratios for clinical outcomes with warfarin versus direct oral anticoagulants in severe tricuspid regurgitation 30
Table 4. Hazard ratios for clinical outcomes by on-label dose and off-label underdose direct oral anticoagulants versus warfarin in the total study population 31
Table 5. Hazard ratios for primary outcomes with direct oral anticoagulants versus warfarin by subgroup 33
Supplementary Table 1. Standardized mean differences in the variables included in the inverse propensity score weighting before and after adjustment in the total population. 44
Supplementary Table 2. Standardized mean differences in variables included in the inverse propensity score weighting before and after adjustment in severe tricuspid regurgitation. 46
Supplementary Table 3. Standardized mean differences in variables included in the inverse propensity score weighting before and after adjustment by warfarin versus on-label dose and off-label underdose direct oral anticoagulants in the total population. 48
Supplementary Table 4. Incidence rate of clinical outcomes with on-label dose and off-label underdose direct oral anticoagulants versus warfarin in the total population 51
Supplementary Table 5. Incidence rate for clinical outcomes with direct oral anticoagulants versus warfarin in subgroups 52
Supplementary Table 6. Hazard ratio for secondary outcomes by subgroups among direct oral anticoagulants versus warfarin 55
Figure 1. Study population flow diagram 36
Figure 2. Weighted cumulative incidence curves of primary outcomes for the DOAC and warfarin groups in moderate to severe TR. (A) Stroke and systemic embolism. (B) Major bleeding 38
Figure 3. Weighted cumulative incidence curves of secondary outcomes for the DOAC and warfarin groups in moderate to severe TR. (A) Intracranial hemorrhage. (B) Gastrointestinal... 39
Figure 4. Hazard ratio of ischemic stroke and systemic embolic events according to subgroups. 40
Figure 5. Hazard ratio of major bleeding according to subgroups. 41
Supplementary Figure 1. Weighted cumulative incidence curves of the primary outcome for the DOAC and warfarin groups in severe TR. (A) Stroke and systemic embolism. (B) Major bleeding 57
Supplementary Figure 2. Weighted cumulative incidence curves of the primary outcome for on-label dose DOAC, off-label underdose DOAC, and warfarin in moderate to severe TR. (A) Stroke and systemic embolism. (B) Major bleeding 58